Approval of efgartigimod alfa injection (subcutaneous injection) for generalized myasthenia gravis in China – Zai Lab + argenx
Zai Lab Limited and argenx announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC), 1,000mg… read more.
